ADMS News and Press, Adamas Pharmaceuticals Inc. From 05/10/21

First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering med...

Palm Beach, FL – May 5, 2021 – Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.  Symptoms generally develop sl...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at ...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss ...

Palm Beach, FL – April 20, 2021 – While this past year living in quarantine during the pandemic did not just create economical damage, and social disruption… it could have also increased new cases of secondary medical results from the pandemic.  According to variou...

Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org ) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced ...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Mee...

Today, we revisit small biopharma name Adamas Pharmaceuticals for the first time in a couple of years. The company managed to see sales traction from GOCOVRI in 2020 despite the pandemic, and the drug just got approved for a new indication as well. A full investment analysis follo...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at ...

Disclosing new data from two pivotal, Phase 3 clinical studies, Adamas Pharmaceuticals ([[ADMS]] -5.1%) said that its FDA approved therapy Gocovri (amantadine) to treat dyskinesia in Parkinson’s disease demonstrated an additional 2.9 hours ON time without dyskinesia in PD patients...